PUMA
16.5.2023 15:41:29 CEST | Business Wire | Press release
Global sports company PUMA and absorbent apparel brand, Modibodi® are launching the third drop of their best-selling active period underwear range; combining Modibodi’s unique, patented technology with world-class expertise from PUMA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005712/en/
Global sports company PUMA and absorbent apparel brand, Modibodi® are launching the third drop of their best-selling active period underwear range; combining Modibodi’s unique, patented technology with world-class expertise from PUMA. (Photo: Business Wire)
Ever worn white or tight sports uniforms that made you feel uncomfortable about leaking when playing on your period? Or felt exposed in sportswear that left the wings and strings of your disposables on display?
From archaic sports codes to national team uniform fines, athletes are often told to keep playing on their period, when what they’re told to wear makes it extremely uncomfortable and anxiety-inducing.
But that’s about to change. Enter PUMA x Modibodi active period underwear. The new PUMA x Modibodi active period underwear is in league of its own – made for maximum protection and performance on and off the court, field or gym floor. The collection combines soft, breathable fabrics that stretch and move with your body with Modibodi’s concealed absorbent lining, proven to keep you free from leaks, sweat and discharge.
Modibodi Ambassador and Brisbane City FC Captain, Jamilla Riley, says: “As someone who menstruates and plays soccer in a white uniform, I can attest to the discomfort and anxiety that combination can create, particularly when you are young. You spend your time shamed by the fear of leaks, and it can take all your mental strength to refocus on the game at hand. That’s why I’m such an advocate of the new PUMA x Modibodi active period undies. The designs not only bring some much-needed innovation to the sportswear market, but they also help support your menstruating body so you can play without fear of leaking and kick some goals. Who knew playing on your period could be this comfy It’s liberating!”
Modibodi Design and Innovation Director, Charissa Lanham says: “We wanted to destigmatise the challenges of menstruating whilst competing and show athletes a new world in which they can feel confident and supported to play while they bleed. We worked with PUMA to design a range of active period underwear that utilises Modibodi’s world-first patented technology which includes a leak-proof barrier layer for secure protection; meaning athletes can focus on their game, not their period.”
A workout staple, the PUMA x Modibodi collection absorbs fast and offers peace of mind on the pitch by replacing the need for disposable pads, liners and tampons as you play. The super slim, absorbent black lining is designed to help prevent leaks and unwanted stains. Featuring 3 layers of built-in technology that can hold up to 15ml (or 2-3 tampons) without staining your activewear or sports uniform.
To ensure comfort, each design is crafted from 82% recycled material, includes a wider logo waist band for security whilst playing and an aerated mesh side panel to maximise airflow. Modibodi’s proprietary Modifier Technology™ then works to wick moisture and sweat, locking away fluid and odour to keep you feeling fresh and dry.
Available in a two-colour ways Black/Platinum Grey and Black/Green, the collection consists of 3 styles in a range of Light-Moderate to Moderate-Heavy absorbencies, making them ideal to absorb your period and sweat, and keep you fresh and dry, way beyond the final whistle.
The PUMA x Modibodi collection is available online at modibodi.com.
The PUMA x Modibodi collection is available in selected stores and online at puma.com and modibodi.com.
PUMA |
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
MODIBODI |
Since 2013, Modibodi® has had one goal – to make changing the world as easy as changing your underwear. What they didn’t realise, is that in doing so, they’d change the lives of their customers along the way.
Life-changing is the number one phrase heard from Modibodi customers. It’s a language woven into the brand’s DNA and sits firmly at the heart of what they do. Having made a name for itself globally, designing confidence-shaping, confidence-creating, planet-sustaining, life-changing apparel, Modibodi® offers comfort from periods, pee and bodily leaks, and champions conversations and initiatives that allow people to live more comfortably in themselves.
Designed with compassion and offering a sustainable solution to disposable products, Modibodi uses proprietary innovation and patented technology to ensure each and every one of their designs is market leading, saving billions of single-use disposable hygiene products from ending up in landfill.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005712/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
